Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses

Carrade, Danielle D.; Owens, Sean D.; Galuppo, Larry D.; Vidal, Martin A.; Ferraro, Gregory L.; Librach, Fred; Buerchler, Sabine; Friedman, Michael S.; Walker, Naomi J.; Borjesson, Dori L.

doi:10.3109/14653249.2010.536213

Cited by 128 publications

(138 citation statements)

References 48 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, injection of allogeneic placentally-derived MSCs into equine joints resulted in self-limiting inflammatory responses with no difference in the type or severity of the inflammatory response elicited by autologous versus allogeneic MSCs [72]. …”

Section: Clinical Impressions and Future Implicationsmentioning

confidence: 93%

The Regenerative Medicine Laboratory: Facilitating Stem Cell Therapy for Equine Disease

Borjesson

Peroni

2011

Clinics in Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Section: Clinical Impressions and Future Implicationsmentioning

confidence: 93%

The Regenerative Medicine Laboratory: Facilitating Stem Cell Therapy for Equine Disease

Borjesson

Peroni

2011

Clinics in Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

“…Others: SOX2+ [9][10][11][12] Swine Embryonic cell markers: OCT-3/4+ Others: SOX2+, NANOG+ [8] As in human medicine (for review see [7,15,16]), also in veterinary medicine an important property to evaluate stem cells is to assess their usefulness in allogenic regenerative medicine. To test the immunological properties of UCM-derived cells, Carrade et al, (2010) studied healthy horses following a single intra-articular injection of autologous and allogeneic MSCs from equine UCM and found no significant differences between the degree and type of inflammation elicited by self and non-self-MSC [17].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Studies of Horse Umbilical Cord Matrix-Derived Cells: From Characterization to Labeling for Magnetic Resonance Imaging

Consiglio

Corradetti

Rutigliano

et al. 2011

TOTERMJ

View full text Add to dashboard Cite

Despite the increasing use of cell-based therapies for equine orthopedic problems, many questions remain to be answered, such as what is: the optimal cell source for particular injuries, the best timing and route of treatment and the long-term safety and efficacy of the procedure? Previously, equine mesenchymal stem cells (MSCs) have most frequently been isolated from bone marrow (BM) and adipose tissue. However, these cells have limited potential in terms of in vitro proliferation ability and differentiation capacity with increasing donor age and in vitro passage number. In addition, procurement of BM-derived cells in horses requires an invasive BM aspiration procedure which has been associated with pneumopericardium. Fetal adnexa could provide a useful alternative source of MSCs avoiding these limitations. To investigate this, we isolated and characterized presumptive stem cells from the intervascular and perivascular portions of equine umbilical cord matrix using enzymatic digestion. The cells isolated from the intervascular portion showed faster doubling times than cells from the perivascular portion (which are probably more highly differentiated). Cells from both portions expressed MSC mRNA markers (CD29, CD105, CD44, CD166) and were negative for CD34 and MHC-II. Osteogenic, adipogenic, chondrogenic and neurogenic differentiation were confirmed by specific staining and gene expression.To investigate the potential of umbilical cord-derived cells for use in cell therapies, pre-clinical experiments involving labeling of cells with magnetic resonance contrast agents (superparamagnetic iron oxide particles -SPIO -and manganese chloride) and the subsequent in vitro study of these were conducted. The SPIO labeling procedure proved to be an efficient and non toxic tool that merits further investigation and the possible development of in vivo studies.

show abstract

“…Intra-articular injection of both types of MSC elicited synovial swelling, but there were no significant differences between the synovial effects of allogenic or autologous cells. These results open a new avenue for the treatment of joint diseases with allogenic stem cell therapies (Carrade et al 2011).…”

Section: Autologous Conditioned Serum (Acs)mentioning

confidence: 99%

Therapies intended for joint regeneration in the horse

2013

View full text Add to dashboard Cite

RESUMENLas cojeras constituyen la principal causa de consulta en clínica equina y la osteoartritis (OA) representa cerca del 60 % de los casos. Durante la última década se han presentado avances significativos en nuestro entendimiento de la fisiopatología de la OA. Sin embargo, se ha avanzado muy poco en el desarrollo de tratamientos efectivos que no solo alivien el dolor y la inflamación asociados al problema, sino que también limiten los cambios degenerativos o incluso promuevan la regeneración de los tejidos articulares afectados por esta enfermedad crónica inflamatoria. Por otra parte, estos tratamientos deberían ser libres de efectos adversos como trastornos gastrointestinales, daño renal e inmunosupresión. El actual conocimiento de proteínas y células comprometidas en la biología de las enfermedades musculo-esqueléticas, como la OA, han permitido el desarrollo de nuevos enfoques terapéuticos desde el punto de vista experimental y clínico. El objetivo de esta revisión es presentar estado del arte de la terapia regenerativa articular en el caballo.Palabras clave: caballo, osteoartritis, medicina regenerativa. SUMMARYLameness is the main cause of consultation in the current equine clinic, and osteoarthritis (OA) represents about 60% of cases. During the last decade, there have been significant advances in our understanding of the pathophysiology of OA. However, there has been little progress in the development of effective treatments that not only relieve pain and inflammation associated with the problem, but also limit degenerative changes, or even promote regeneration in joint tissues affected by this chronic and inflammatory disease. These treatments should be free of side effects such as gastrointestinal disorders, kidney damage and immunosuppression. Current knowledge about the proteins and cells involved in the biology of musculoskeletal diseases, such as OA, has allowed the development of new therapeutic approaches from an experimental and clinical viewpoint. The aim of this review is to present the state of the art for regenerative therapy of joints in the horse.

show abstract

Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses

Cited by 128 publications

References 48 publications

The Regenerative Medicine Laboratory: Facilitating Stem Cell Therapy for Equine Disease

The Regenerative Medicine Laboratory: Facilitating Stem Cell Therapy for Equine Disease

In Vitro Studies of Horse Umbilical Cord Matrix-Derived Cells: From Characterization to Labeling for Magnetic Resonance Imaging

Therapies intended for joint regeneration in the horse

Contact Info

Product

Resources

About